Literature DB >> 22687508

Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.

Laura E Via1, Dan Schimel, Danielle M Weiner, Veronique Dartois, Emmanuel Dayao, Ying Cai, Young-Soon Yoon, Matthew R Dreher, Robin J Kastenmayer, Charles M Laymon, J Eoin Carny, Joanne L Flynn, Peter Herscovitch, Clifton E Barry.   

Abstract

With a host of new antitubercular chemotherapeutics in development, methods to assess the activity of these agents beyond mouse efficacy are needed to prioritize combinations for clinical trials. Lesions in Mycobacterium tuberculosis-infected rabbits are hypoxic, with histopathologic features that closely resemble those of human tuberculous lesions. Using [(18)F]2-fluoro-deoxy-d-glucose ([(18)F]FDG) positron emission tomography-computed tomography (PET-CT) imaging, we studied the dynamics of tuberculosis infection in rabbits, revealing an initial inflammatory response followed by a consolidative chronic disease. Five weeks after infection, as much as 23% of total lung volume was abnormal, but this was contained and to some extent reversed naturally by 9 weeks. During development of this chronic state, individual lesions in the same animal had very different fates, ranging from complete resolution to significant progression. Lesions that remained through the initial stage showed an increase in volume and tissue density over time by CT. Initiation of chemotherapy using either isoniazid (INH) or rifampin (RIF) during chronic infection reduced bacterial load with quantitative changes in [(18)F]FDG uptake, lesion density and total lesion volume measured by CT. The [(18)F]FDG PET uptake in lesions was significantly reduced with as little as 1 week of treatment, while the volume and density of lesions changed more slowly. The results from this study suggest that rabbits may be a useful surrogate species for evaluating novel chemotherapies and understanding changes in both PET and CT scans in human clinical trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687508      PMCID: PMC3421588          DOI: 10.1128/AAC.00531-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  A nested case-control study on treatment-related risk factors for early relapse of tuberculosis.

Authors:  Kwok C Chang; Chi C Leung; Wing W Yew; Suzanne C Ho; Cheuk M Tam
Journal:  Am J Respir Crit Care Med       Date:  2004-09-16       Impact factor: 21.405

2.  Virulence of Mycobacterium tuberculosis CDC1551 and H37Rv in rabbits evaluated by Lurie's pulmonary tubercle count method.

Authors:  W R Bishai; A M Dannenberg; N Parrish; R Ruiz; P Chen; B C Zook; W Johnson; J W Boles; M L Pitt
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death.

Authors:  L Tsenova; K Sokol; V H Freedman; G Kaplan
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

4.  Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli.

Authors:  P J Converse; A M Dannenberg; J E Estep; K Sugisaki; Y Abe; B H Schofield; M L Pitt
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

5.  Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.

Authors:  K A Padgaonkar; S N Revankar; A D Bhatt; J A Vaz; N D Desai; S D'Sa; V Shah; K Gandewar
Journal:  Int J Tuberc Lung Dis       Date:  1999-07       Impact factor: 2.373

Review 6.  Inflammation imaging.

Authors:  Hazel A Jones
Journal:  Proc Am Thorac Soc       Date:  2005

Review 7.  OsiriX: an open-source software for navigating in multidimensional DICOM images.

Authors:  Antoine Rosset; Luca Spadola; Osman Ratib
Journal:  J Digit Imaging       Date:  2004-06-29       Impact factor: 4.056

8.  Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity.

Authors:  In-Ju Kim; Jung Sub Lee; Seong-Jang Kim; Yong-Ki Kim; Yeon Joo Jeong; Sungmin Jun; Hyun Yul Nam; Ju Sung Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-18       Impact factor: 9.236

9.  Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system.

Authors:  L Tsenova; A Bergtold; V H Freedman; R A Young; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  On the response of genetically resistant and susceptible rabbits to the quantitative inhalation of human type tubercle bacilli and the nature of resistance to tuberculosis.

Authors:  M B LURIE; S ABRAMSON; A G HEPPLESTON
Journal:  J Exp Med       Date:  1952-02       Impact factor: 14.307

View more
  52 in total

Review 1.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

2.  Computed Tomography-Based Biomarker for Longitudinal Assessment of Disease Burden in Pulmonary Tuberculosis.

Authors:  P M Gordaliza; A Muñoz-Barrutia; L E Via; S Sharpe; M Desco; J J Vaquero
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

Review 3.  In Vitro Granuloma Models of Tuberculosis: Potential and Challenges.

Authors:  Paul Elkington; Maria Lerm; Nidhi Kapoor; Robert Mahon; Elsje Pienaar; Dongeun Huh; Deepak Kaushal; Larry S Schlesinger
Journal:  J Infect Dis       Date:  2019-05-24       Impact factor: 5.226

4.  Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.

Authors:  Meenal Datta; Laura E Via; Walid S Kamoun; Chong Liu; Wei Chen; Giorgio Seano; Danielle M Weiner; Daniel Schimel; Kathleen England; John D Martin; Xing Gao; Lei Xu; Clifton E Barry; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

5.  Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice.

Authors:  Alvaro A Ordonez; Supriya Pokkali; Vincent P DeMarco; Mariah Klunk; Ronnie C Mease; Catherine A Foss; Martin G Pomper; Sanjay K Jain
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

6.  A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets.

Authors:  Laura E Via; Kathleen England; Danielle M Weiner; Daniel Schimel; Matthew D Zimmerman; Emmanuel Dayao; Ray Y Chen; Lori E Dodd; Mike Richardson; Katherine K Robbins; Ying Cai; Dima Hammoud; Peter Herscovitch; Véronique Dartois; JoAnne L Flynn; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

7.  [18F]-Fluorodeoxyglucose Uptake in Lymphoid Tissue Serves as a Predictor of Disease Outcome in the Nonhuman Primate Model of Monkeypox Virus Infection.

Authors:  Julie Dyall; Reed F Johnson; Svetlana Chefer; Christopher Leyson; David Thomasson; Jurgen Seidel; Dan R Ragland; Russell Byrum; Catherine Jett; Jennifer A Cann; Marisa St Claire; Elaine Jagoda; Richard C Reba; Dima Hammoud; Joseph E Blaney; Peter B Jahrling
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

Review 8.  Convergence of non-communicable diseases and tuberculosis: a two-way street?

Authors:  M J Magee; A D Salindri; U P Gujral; S C Auld; J Bao; J S Haw; H-H Lin; H Kornfeld
Journal:  Int J Tuberc Lung Dis       Date:  2018-11-01       Impact factor: 2.373

Review 9.  Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration.

Authors:  Joseph E Qualls; Peter J Murray
Journal:  Semin Immunopathol       Date:  2015-10-21       Impact factor: 9.623

10.  Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus).

Authors:  Laura E Via; Danielle M Weiner; Daniel Schimel; Philana Ling Lin; Emmanuel Dayao; Sarah L Tankersley; Ying Cai; M Teresa Coleman; Jaime Tomko; Praveen Paripati; Marlene Orandle; Robin J Kastenmayer; Michael Tartakovsky; Alexander Rosenthal; Damien Portevin; Seok Yong Eum; Saher Lahouar; Sebastien Gagneux; Douglas B Young; Joanne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.